SpeeDx Build Further Coverage in SARS-CoV-2 Genotyping Reagent Portfolio
6.10.2021 09:00:00 EEST | Business Wire | Press release
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, have further expanded their product line of research reagents for COVID-19 variant analysis to include a key characteristic mutation connected to the SARS-CoV-2 Lambda variant of interest (VOI). The Plex Prime® SARS-CoV-2 Genotyping* product line has rapidly expanded since launching in July, utilising the company’s unique universal substrate approach and patented multiplexing technology. The suite of products can be used independently or combined to support laboratory investigation and monitoring efforts of key SARS-CoV-2 variants of interest or concern.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211005006261/en/
PlexPrime® SARS-CoV-2 L452Q Lambda* is a single well mix designed to detect the L452Q spike mutation of SARS-CoV-2 found in the C.37 variant of interest (Lambda)1, in addition to an RdRp gene target of SARS-CoV-2. This reagent is the third product in the PlexPrime® SARS-CoV-2 Genotyping portfolio and can be used as a stand-alone reflex or combined with PlexPrime® SARS-CoV-2 Alpha/Beta/Gamma+, and/or the PlexPrime®P681R Delta reagents. (Photo: Business Wire)
“Rapid screening of positive samples with a PCR-based approach allows laboratories to easily monitor mutations as they circulate” said Dr Charles Cartwright, SpeeDx Senior Vice President of Clinical Affairs. “The individual mutations targeted with our suite of genotyping reagents have been carefully chosen to represent key lineage divergence, thus we are finding that even the latest emerging variants of interest and concern can be targeted for further analysis with our existing portfolio.”
Plex Prime® SARS-CoV-2 L452Q Lambda* is a single well mix designed to detect the L452Q spike mutation of SARS-CoV-2 found in the C.37 variant of interest (Lambda)1, in addition to an RdRp gene target of SARS-CoV-2. This reagent is the third product in the Plex Prime® SARS-CoV-2 Genotyping portfolio and can be used as a stand-alone reflex or combined with Plex Prime® SARS-CoV-2 Alpha/Beta/Gamma+, and/or the Plex Prime®P681R Delta reagents. Compatible with standard qPCR and liquid handling instrumentation, the Plex Prime® SARS-CoV-2 Genotyping will reduce the costs and manual processes for laboratories currently practicing high-volume sequence analysis.
About SpeeDx
Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see: https://plexpcr.com
*available as Research Use Only reagents not for use in diagnostic procedures
References
- Tracking SARS-CoV-2 variants. World Health Organisation. Found at: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211005006261/en/
Contact information
Madeline O’Donoghue - SpeeDx Global Marketing Director
madelineo@speedx.com.au
+61 406 582 808
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ZincFive Expands Nickel-Zinc Technology into In-Rack Backup and AI Dynamic Power Solutions28.9.2026 15:05:00 EEST | Press release
ZincFive®, the leader in nickel-zinc (NiZn) battery-based solutions for immediate power applications, today announced its expansion into in-rack energy storage with the development of Battery Backup Unit (BBU) and AI Dynamic Power Module (DPM) solutions designed to address the evolving energy storage requirements of AI data centers. As AI drives higher rack power densities and increasingly dynamic workloads, data center power architectures are evolving to manage both traditional backup requirements and rapid, repeated changes in power demand. These transient loads can place significant stress on electrical infrastructure, creating a growing need for power solutions closer to the rack that can respond quickly, safely, and reliably. Today’s rack-level technologies often require tradeoffs between energy capacity and dynamic power response. Traditional BBUs are primarily designed to provide backup runtime, while capacitor-based systems offer rapid response but limited energy duration and s
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta Virus28.9.2026 15:00:00 EEST | Press release
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced the primary endpoint was met in the Phase 3 portion of the AZURE-1 study evaluating brelovitug, an investigational fully human monoclonal antibody that binds to hepatitis B surface antigen (HBsAg), for the treatment of chronic hepatitis delta virus (HDV). In addition, 48-week data from the Phase 2b portion of AZURE-1 demonstrated deepening viral suppression, with a greater proportion of patients achieving HDV RNA below the lower limit of quantification (LLOQ, <10 IU/mL) and target not detected (TND), and increased rates of alanine aminotransferase (ALT) normalization. AZURE-1 is one of two pivotal Phase 3 studies intended to form the basis of Mirum’s U.S. registration package for brelovitug. “These results demonstrate the potential of brelovitug as a well-tolerated, convenient, single agent to deliver both deep viral suppression and ALT normalization, with responses that continue to deepen throu
Oscilloquartz and Iridium expand resilient positioning and navigation capabilities with new PNT service integration28.9.2026 15:00:00 EEST | Press release
Oscilloquartz today announced the next phase of its collaboration with Iridium Communications Inc., expanding the range of Iridium® positioning, navigation and timing (PNT) (formerly Iridium Satellite Time and Location® or STL®) capabilities available across its synchronization portfolio. The latest integration brings resilient positioning and navigation alongside trusted timing to a broader range of applications. Building on the companies’ existing collaboration, it strengthens end-to-end, multi-layered assured PNT architectures for critical infrastructure, defense and other GNSS-dependent applications. “Organizations are adopting layered PNT architectures to improve resilience and reduce dependence on any single timing or positioning source,” said Rohit Braggs, VP of PNT at Iridium. “Working with Oscilloquartz extends the reach of Iridium® PNT services, making it easier for customers to deploy resilient, multi-source PNT architectures.“ Expanded support for Iridium® PNT services exte
Mirion Technologies to Host Inaugural Mirion Connect EMEA/APAC Conference in Brussels28.9.2026 15:00:00 EEST | Press release
Mirion Technologies, a leading provider of advanced radiation safety solutions, today announced Mirion Connect 2026 EMEA/APAC, the company’s first regional edition of its Mirion Connect conference for Europe, the Middle East, Africa and Asia-Pacific region. The event will take place September 29 – October 1, 2026, in Brussels, Belgium. Mirion Connect, an event hosted in the United States for 40 years, brings together nuclear and radiation safety professionals from around the world for a week of expert-led presentations, open-forum discussions, hands-on technical training and targeted breakout sessions. Expanding to Europe, the event is designed to give attendees direct access to the latest developments in radiation detection, measurement and safety technologies, alongside practical guidance they can apply immediately in their own operations. The conference theme — Bound by our history, inspired by the future we shape together — is based upon deep industry partnerships and unites attend
Xceedance Reports 35-50% Efficiency Gains in Insurance Operations Through AI Orchestration28.9.2026 15:00:00 EEST | Press release
Xceedance said today that AI orchestration is producing measurable efficiency gains in live insurance operations, delivered through Orchestrated Intelligence, its operating model, and IAN, its agent studio for insurance. In agency and broker operations, processes moved onto IAN delivered around 35% efficiency improvement from the point of go-live. As these implementations have matured, some are now approaching 50%. Xceedance is seeing the same pattern in underwriting support for excess and surplus lines carriers. The company is also deploying AI at scale in claims third-party administration (TPA) operations, where the volume of repeatable work is large. A significant portion of gains comes from Xceedance teammates continuously refining AI-enabled workflows — correcting output, resolving the exceptions AI cannot handle, and incorporating those learnings into workflows and agent configurations. As processes mature, a greater proportion of routine work can be completed automatically, allo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom